CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Tempus to acquire cancer test maker Personalis for $1.5B

Positive
AI Analysis

Summary

Tempus AI announced a $1.5B acquisition of cancer test maker Personalis, reflecting growing industry interest in blood-based cancer diagnostic tests.

Importance:7/10
Sentiment:
0.50
cancer diagnosticsblood-based testingM&Apersonalized medicine
Related Companies

Read the original article

Published by BioPharma Dive on July 20, 2026 6:38 PM

Read Original